Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2025-02-28 00:00:00 ET · period of report 2025-02-26 · accession 0000950170-25-030041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-28 | 2025-02-26 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +145.2K | 246.4K | +144% | $0 |
| D | 2025-02-28 | 2025-02-26 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +290.5K | 290.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-26 | A | A | 145,250 | $0.00 | 246,380 | D | — | — | (F1) Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. (F2) Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-26 | A | A | 290,500 | $0.00 | 290,500 | D | $1.13 · — to 2035-02-25 | 290,500 Common Stock | (F6) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. |